In vitro studies on the cardiotoxicity of chemotherapeutics

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Cellular responses to toxic agents involve the de novo synthesis of 'shock proteins'.
• This 'shock protein' induction serves as a sensitive indicator of toxicity at the protein synthesis level.
• Cardiac myocytes are crucial for cardiovascular function, and their sensitivity to chemotherapeutics is a significant clinical concern.

Purpose of the Study:

• To investigate the cardiotoxic effects of various chemotherapeutic drugs on cultured cardiac myocytes.
• To evaluate the utility of 'shock protein' synthesis as a biomarker for chemotherapy-induced cardiotoxicity.
• To elucidate the mechanisms underlying cardiotoxicity for specific chemotherapeutic agents.

Main Methods:

• Utilized cultured cardiac myocytes as a model system to assess drug toxicity.
• Measured the de novo synthesis of 'shock proteins' in response to chemotherapeutic agents.
• Determined the concentrations of chemotherapeutics that induce or inhibit protein synthesis.

Main Results:

• Cisplatin and methotrexate induced the formation of a 30-kilodalton 'shock protein' at specific concentrations (≥16 µmol/l and ≥1.4 µmol/l, respectively).
• Doxorubicin and daunomycin significantly inhibited protein synthesis in cardiac myocytes at concentrations ranging from 0.8–80 µmol/l and 0.9–90 µmol/l.
• Other tested chemotherapeutics did not affect heart cell protein formation at concentrations exceeding pharmacological levels.

Conclusions:

• Anthracycline cardiotoxicity (doxorubicin, daunomycin) likely stems from the profound depression of protein synthesis.
• Cisplatin and methotrexate may exhibit cardiotoxicity, particularly at elevated concentrations.
• 'Shock protein' induction serves as a valuable indicator for detecting potential cardiotoxicity of chemotherapeutic agents.